Outlook Therapeutics (OTLK) announced the appointment of Bob Jahr as Chief Executive Officer, CEO. Mr. Jahr has also been appointed to the Outlook Therapeutics Board of Directors. Lawrence Kenyon, who has served as Outlook Therapeutics’ Chief Financial Officer, CFO, and interim CEO, will continue serving as CFO and as a member of the Board of Directors. Jahr joins Outlook Therapeutics having most recently served as the Chief Commercial Officer for Sobi North America
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Outlook Therapeutics announces SMC recommendation of LYTENAVA
- Outlook Therapeutics Launches LYTENAVA in Europe
- Outlook Therapeutics announces commercial launch of LYTENAVA in Germany, UK
- Outlook Therapeutics Announces New Stock and Warrant Offering
- Outlook Therapeutics 9.3M share Spot Secondary priced at $1.40